Safety and Feasibility of Combined Granulocyte Colony.pdf

112 ORIGINAL ARTICLE Safety and Feasibility of Combined Granulocyte Colony Stimulating Factor and Erythropoetin Based-Stem Cell Therapy Using Intracoronary Infusion of Peripheral Blood Stem Cells in Patients with Recent Anterior Myocardial Infarction: One-Year Follow-up of A Phase 1 Study Teguh Santoso*, Cosphiadi Irawan*, Idrus Alwi*, Auda Aziz**, Agus Kosasih**, Sri Inggriani***, Ardian Saputra***, Merry Wintery***, Linda Lison*** *Department of Internal Medicine, University of Indonesia, Faculty of Medicine - Dr. Cipto Mangunkusumo Hospital. Jl. Diponegoro no. 71, Jakarta, Indonesia. ** Dharmais Cancer Hospital, Jakarta, Indonesia. *** Medistra Hospital, Jakarta, Indonesia. Correspondence mail to: tsantoso@cbn.net.id INTRODUCTION Current practice guidelines emphasize the importance of achieving reperfusion of the infarct- related artery (IRA) as early as possible.1-3 However, primary percutaneous coronary intervention (PCI) is performed at less than 25% of acute care hospitals in the United States.4,5 Many patients with myocardial infarction with ST-segment elevation present to hospitals that do not have the capability of performing PCI and, therefore, cannot undergo PCI within the timelines recommended in the guidelines.1-3 Instead, they receive thrombolytics as the initial reperfusion therapy. A report from the National Registry of Myocardial Infarction showed that 27.6% of the AMI patients received thrombolytic therapy in 2006.6 However, angiographic studies have shown that coronary reperfusion does not occur in 20% to 45% of patients receiving thrombolytic therapy.7 In addition, ABSTRACT Aim: to assess the safety and feasibility of combined granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) based intracoronary peripheral blood stem cells (PBSCs) therapy in patients with recent myocardial infarction (RMI) who had successful reperfusion therapy with drug-eluting stent. Methods: a total of 18 patients diagnosed